Updated Financial Standings, Company Announcements, and Customer-Centered Suggestions - Research Report on Perrigo, Thermo Fisher, DaVita, United Therapeutics, and Keryx Biopharmaceuticals
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, December 20, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Perrigo Co. (NYSE: PRGO), Thermo Fisher Scientific, Inc. (NYSE: TMO), DaVita, Inc. (NYSE: DVA), United Therapeutics Corporation (NASDAQ: UTHR), and Keryx Biopharmaceuticals Inc. (NASDAQ: KERX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Perrigo Co. Research Report
On December 17, 2013, Perrigo Co.'s (Perrigo) stock increased 1.46%, ending the day at $153.25. Over the previous three trading sessions, shares of Perrigo declined 0.28%, compared to the Dow Jones Industrial Average which increased 0.86% during the same period. The Full Research Report on Perrigo Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.AnalystsCorner.com/r/full_research_report/4168_PRGO
Thermo Fisher Scientific, Inc. Research Report
On December 17, 2013, Thermo Fisher Scientific, Inc.'s (Thermo Fisher) stock increased 0.08%, ending the day at $102.32. Over the previous three trading sessions, shares of Thermo Fisher increased 2.09%, compared to the Dow Jones Industrial Average which also increased 0.86% during the same period. The Full Research Report on Thermo Fisher Scientific, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.AnalystsCorner.com/r/full_research_report/45ed_TMO
DaVita, Inc. Research Report
On December 17, 2013, DaVita, Inc. (DaVita) reported that it is dedicated to giving useful tips on winter travel, holiday cooking recipes, and dialysis-friendly gifts. DaVita stated that it encourages patients traveling this holiday season to make and follow a travel checklist - taking note of coordinating with their care team, looking for a convenient dialysis center in the area to which they are traveling (even as a Plan B for those on home modality options), and taking along extra medication and medical information. Patients with wheelchairs or those taking their dialysis equipment along should allow extra time at the airport. Dyane Shanahan, franchisee business owner and DaVita dialysis patient, commented, "Traveling can be stressful, especially during the holidays, but also allows freedom and a chance to return to normalcy for the holidays. As a part-time travel agent, I've been fortunate to travel nationally and internationally and it helps me get back a part of my life before dialysis." Duane Dunn, Director of social work services at DaVita, added, "Patients spend hours on dialysis, whether that is in-center three times a week or at home, so receiving gifts that make their lives easier or help pass the time while they're on dialysis is definitely appreciated. Patients also are often cold, so warm clothing or blankets could be greatly beneficial in making them as comfortable as possible during their treatments." The Full Research Report on DaVita, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.AnalystsCorner.com/r/full_research_report/5986_DVA
United Therapeutics Corporation Research Report
On December 17, 2013, United Therapeutics Corporation's (United Therapeutics) stock declined 2.88%, ending the day at $85.89. Over the previous three trading sessions, shares of United Therapeutics declined 5.25%, compared to the Nasdaq Composite which increased 0.63% during the same period. The Full Research Report on United Therapeutics Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.AnalystsCorner.com/r/full_research_report/e4cc_UTHR
Keryx Biopharmaceuticals Inc. Research Report
On December 17, 2013, Keryx Biopharmaceuticals Inc.'s (Keryx Biopharmaceuticals) stock declined 0.32%, ending the day at $12.46. Over the previous three trading sessions, shares of Keryx Biopharmaceuticals increased 1.88%, compared to the Nasdaq Composite which also increased 0.63% during the same period.
The Full Research Report on Keryx Biopharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.AnalystsCorner.com/r/full_research_report/27d2_KERX
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
http://www.AnalystsCorner.comSOURCE Analysts' Corner
Share this article